Zobrazeno 1 - 10
of 388
pro vyhledávání: '"Acute myelogenous leukemia (AML)"'
Autor:
Aaron D. Schimmer, Sara Mirali
Publikováno v:
Stem Cells Translational Medicine
The biological function of most mitochondrial proteases has not been well characterized. Moreover, most of the available information on the normal function of these proteases has been derived from studies in model organisms. Recently, the mitochondri
Publikováno v:
Annals of Palliative Medicine. 10:7884-7893
BACKGROUND A meta-analysis was performed to examine the clinical efficacy of drugs in the treatment of acute myelogenous leukemia (AML). METHODS combinations of terms of "acute myeloid leukemia", "fludara", "cytarabine", "cladribine", "aclacinomycin"
Publikováno v:
Sultan Qaboos University Medical Journal, Vol 12, Iss 4, Pp 498-502 (2012)
An extremely premature male neonate presented with an unusual multisystem dysfunction within the first 24 to 48 hours of life. The unfolding of clinical events and investigations revealed a transient myeloproliferative disorder (TMD). TMD was the mai
Externí odkaz:
https://doaj.org/article/5aa70e27a79549a592ca52c514cc0bef
Autor:
Ram W. Sabnis
Publikováno v:
ACS Med Chem Lett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4315f7f43241715d1360f7acb0668ff8
https://europepmc.org/articles/PMC8591715/
https://europepmc.org/articles/PMC8591715/
Publikováno v:
Cardiovasc Diagn Ther
Acute myelogenous leukemia (AML) is a malignant disease of the hematopoietic system, characterized by features of bone marrow insufficiency and organ infiltration by leukemic cells. Venous thrombosis in AML patients is uncommon, compared to bleeding;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::675f086d07e4cdb01dd469d2c296ae4a
https://europepmc.org/articles/PMC7666938/
https://europepmc.org/articles/PMC7666938/
Autor:
Osnat Bohana-Kashtan, Margaret M. Showel, Martin S. Tallman, Jessica K. Altman, Abi Vainstein-Haras, James M. Foran, Avichai Shimoni, Arnon Aharon, Michal Abraham, Yaron Pereg, Shaul Kadosh, Arnon Nagler, Ella Sorani, Yishai Ofran, Galia Oberkovitz, Naveen Pemmaraju, Amnon Peled, Ahmed AlRawi, Emil Samara, Geoffrey L. Uy, Tzipi Lustig, Michael Andreeff, Irit Glicko-Kabir, Stephen Shaw, Jorge E. Cortes, Carlos E. Bueso-Ramos, Adam Foley-Comer, Gautam Borthakur, John F. DiPersio, Jacob M. Rowe
Publikováno v:
CancerReferences. 127(8)
Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high-affinity CXCR4 antagonist BL-8040 with high-
Autor:
Bruno C. Medeiros, Michaela Liedtke, Anjali S. Advani, Megan Othus, Kristen M. O'Dwyer, Hongli Li, Harry P. Erba, Frederick R. Appelbaum, Alan F. List, Laura C. Michaelis
Publikováno v:
Leukemia Research. 67:17-20
Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75%
Publikováno v:
Gene Reports. 25:101310
Objective To standardize simple PCR based technique to identify FLT3 mutations in patients with newly diagnosed acute myelogenous leukemia (AML). Material and methods Thirty six patients with different chromosomal presentation were included in the st
Autor:
Yener Koc, Aleksandr D. Kulagin, Didier Blaise, Jaime Sanz, Montserrat Rovira, Arnon Nagler, Goda Choi, Fabio Ciceri, Hélène Labussière-Wallet, Jan Vydra, Ibrahim Yakoub-Agha, Mohamad Mohty, Myriam Labopin, Péter Reményi
Publikováno v:
Blood. 138:3916-3916
Background: Post-transplant cyclophosphamide (PTCy) has been shown to significantly reduce transplant related mortality (TRM) post hematopoietic stem cell transplantation (HSCT) and is being increasingly used for acute myelogenous leukemia (AML) pati
Autor:
Zartash Gul, Jeanna Wallenta Law, Philip Kuriakose, Michael A. Thompson, Haley McCracken, Sowjanya Vuyyala, Anna B. Berry, Francesca Coutinho, Christopher Willner, Thomas D. Brown, Katherine Geverd, Frank M. Wolf
Publikováno v:
Blood. 138:4443-4443
Background and Objective: Molecular testing and treatment patterns for patients (pts) diagnosed with acute myelogenous leukemia (AML) have evolved over recent years. Next-generation sequencing (NGS) technologies allow for detection of somatic gene al